{"id":388354,"date":"2020-11-25T07:03:23","date_gmt":"2020-11-25T12:03:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388354"},"modified":"2020-11-25T07:03:23","modified_gmt":"2020-11-25T12:03:23","slug":"trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/","title":{"rendered":"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ\/TSX: TRIL), <\/strong>a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020.<\/p>\n

\n TTI-622: <\/strong>
\n Poster <\/strong>
\n Presentation, Publication N<\/strong>
\n umber 1191<\/strong>
\n
\n Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study<\/em>
\n
Presenter: Krish Patel, M.D., Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster I
Date: Saturday, December 5, 2020; available from 10:00AM EST <\/p>\n

\n TTI-621: <\/strong>
\n Oral <\/strong>
\n Presentation<\/strong>
\n ,<\/strong>
\n Publication <\/strong>
\n N<\/strong>
\n umber <\/strong>
\n 646<\/strong>
\n
\n Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies<\/em>
\n
Presenter: Steven M. Horwitz, M.D., Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
Session: 624. Hodgkin Lymphoma and T\/NK Cell Lymphoma\u2014Clinical Studies: Immunotherapy in T\/NK Cell Lymphoma
Date: Monday, December 7, 2020; Presentation at 3:00PM EST<\/p>\n

The presentations will be available in the Events & Presentations section of Trillium\u2019s website<\/a> once released by the American Society of Hematology.<\/p>\n

Trillium will host a conference call on Monday, December 7th<\/sup> at 4:30PM EST.<\/p>\n

International Dial-In Number: +1 236-389-2162
Conference ID: 3169183<\/p>\n

Webcast link:
https:\/\/event.on24.com\/wcc\/r\/2862177\/A91BDB88D738527918C13E289B26CED7<\/a><\/p>\n

\n A<\/strong>
\n bout Trillium Therapeutics<\/strong>
\n
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company\u2019s two clinical programs, TTI-621 and TTI-622,\u00a0target CD47, a \u201cdon\u2019t eat me\u201d signal that cancer cells frequently use to evade the immune system.<\/p>\n

For more information visit: www.trilliumtherapeutics.com<\/a>\u00a0<\/p>\n

\n Investor Relations<\/strong>
\n :<\/strong>
\n
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com<\/a>
www.trilliumtherapeutics.com<\/a> \u00a0<\/p>\n

\n Media Relations:<\/strong>
\n
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ\/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020. TTI-622: Poster Presentation, Publication N umber 1191 Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study Presenter: Krish Patel, M.D., Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WASession: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster IDate: Saturday, December 5, 2020; … <\/p>\n

Continue reading “Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388354","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTrillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ\/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020. TTI-622: Poster Presentation, Publication N umber 1191 Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study Presenter: Krish Patel, M.D., Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WASession: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster IDate: Saturday, December 5, 2020; … Continue reading "Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-25T12:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting\",\"datePublished\":\"2020-11-25T12:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/\"},\"wordCount\":344,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/\",\"name\":\"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=\",\"datePublished\":\"2020-11-25T12:03:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ\/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020. TTI-622: Poster Presentation, Publication N umber 1191 Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study Presenter: Krish Patel, M.D., Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WASession: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Prospective Clinical Trials: Poster IDate: Saturday, December 5, 2020; … Continue reading \"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-25T12:03:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting","datePublished":"2020-11-25T12:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/"},"wordCount":344,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/","name":"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=","datePublished":"2020-11-25T12:03:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MTg5MyMzODQzMDQ1IzIwMjc0ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-to-present-clinical-data-at-the-62nd-american-society-of-hematology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388354"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388354\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}